Background: There are limited nationally representative estimates of the annual economic burden among survivors of the three most prevalent cancers (colorectal, female breast, and prostate) in both nonelderly and elderly populations in the United States.
components of economic burden vary by cancer site in comparison with similar individuals without a cancer history. Moreover, the excess economic burden associated with cancer is likely to vary by age because younger cancer survivors are more likely to receive aggressive treatments than older cancer survivors (1, (11) (12) (13) . Information on the total and excess economic burden by cancer site and age can help plan, implement, and evaluate interventions that target cancer survivors who are most economically vulnerable (4, 14, 15) . To our knowledge, there are limited nationally representative estimates of the total and excess economic burden by cancer site in both nonelderly and elderly populations.
To date, the majority of studies with detailed information on economic burden by cancer site were conducted among elderly Medicare beneficiaries (2, 4, 14, (16) (17) (18) , only addressed medical expenditures, and did not include non-Medicare expenditures from other payers and patient out-of-pocket (OOP) cost, which account for about 40% of total expenditures (3) . Similarly, previous studies examining the economic burden by cancer site among nonelderly cancer survivors were limited to direct medical expenditures and were based on survivors enrolled in health maintenance organizations or employer-based insurance programs (19) (20) (21) . Several of these studies were based on data from the early 1990s and will not reflect contemporary cancer survivorship care (19, 21) . Moreover, productivity losses by cancer site are rarely addressed for nonelderly cancer survivors or for elderly survivors who are still working (15) . Nationally representative estimates of cancer site-specific total and excess medical expenditures and productivity losses among both nonelderly and elderly cancer survivors are important for policy makers to better understand the needs of survivors, prioritize cancer survivorship programs, and monitor the effect public health policies such as the Affordable Care Act (ACA) may have on the economic burden of cancer survivors. However, because of differences in study populations, data sources, measurements of economic burden, and statistical methods, it is difficult to have consistent estimates of the total and excess economic burden across age groups and cancer sites (15, 20, (22) (23) (24) .
Herein, we provide nationally representative estimates of annual total economic burden among colorectal, female breast, and prostate cancer survivors by age group and cancer site. Moreover, we examine the excess economic burden associated with the three most prevalent cancers compared with individuals without a cancer history. In this paper, we report the annual economic burden for cancer survivors, including medical expenditures and productivity losses (employment disability, missed work days, and days stayed in bed).
Methods

Data Sources
The 2008 to 2012 Medical Expenditure Panel Survey (MEPS) Household Component (HC) data were used to identify colorectal, female breast, and prostate cancer survivors and individuals without a cancer history. The MEPS is a nationally representative survey of the US civilian noninstitutionalized population conducted by the Agency for Healthcare Research and Quality (AHRQ). It collects detailed information on demographic characteristics, comorbid conditions, payments for medical care, health insurance coverage, and family income. The survey response rates ranged from 53.5% to 59.3% from 2008 to 2012. A detailed description of the MEPS can be found elsewhere (25) .
In the MEPS, cancer status is self-reported. Survey respondents were asked whether they had ever been told by a doctor or other health professional that they had cancer or a malignancy of any kind, followed by another question about the type of cancer. We identified all adults who reported colorectal, female breast, or prostate cancer among nonelderly (age 18-64 years) and elderly (age 65+ years) survey respondents. The final sample consisted of colorectal (nonelderly: n = 169; elderly: n = 371), breast (nonelderly: n = 777; elderly: n = 791), and prostate (nonelderly: n = 281; elderly: n = 889) cancer survivors and individuals without a cancer history (nonelderly: n = 95 640; elderly: n = 13 792). For breast and prostate cancer survivors, we created comparison groups by stratifying individuals without a cancer history by sex: men (nonelderly: n = 45 465; elderly: n = 5614) and women (nonelderly: n = 50 175; elderly: n = 8178).
Patient-Level Characteristics
Patients' demographic and clinical variables included in the analyses were age (18-49, 50-64, 65-79, or 80+ years), sex, race/ ethnicity (non-Hispanic white or other), educational attainment (≤ high school graduate or ≥ some college), marital status, family income level by quartiles, geographic region (Northeast, Midwest, South, or West), number of comorbid conditions (0, 1, 2, or 3+), and health insurance coverage. Health insurance coverage was defined differently for the two age groups (for nonelderly population: any private or other; for elderly population: Medicare and private or other [Medicare and public, Medicare only, or other]). A treatment status variable was created to identity cancer survivors who were receiving cancer related treatments at the time of the MEPS survey (26) . We used the MEPS medical event files to search for any prescriptions for antineoplastic agents in Prescribed Medicines File or receipt of chemotherapy, radiation therapy, or surgery related to cancer in Outpatient Visits File, Office-Based Medical Provider Visits File, and Hospital Inpatient Stays File. The treatment status variable is highly correlated with time since diagnosis (4). We used age at the time of the survey and age at cancer diagnosis to calculate time since diagnosis. Prior studies using this approach have identified recently diagnosed and previously diagnosed as less two years and two or more years, respectively (3). Therefore, we further stratify the treatment status variable by two years since diagnosis. Figure 1 shows the definitions and relationships of the components of economic burden measured in this study, including medical expenditures and productivity losses. Medical expenditures are payments for health care services provided during the year, including office and inpatient-based and outpatient hospital-based care, home health care, dental services, vision aids, and prescribed medicines. The total medical expenditure was further examined by source of payment (OOP, private health insurance, Medicare, Medicaid, or other) and type of services (ambulatory care, inpatient care, prescription medications, or other services). Ambulatory care included office-based provider visits and outpatient visits. All medical expenditures were adjusted to 2012 dollars using the price indices recommended by the AHRQ for use with the MEPS (27) .
Economic Burden Measures
Productivity losses included monetary measures of probability of employment disability, number of missed work days, and number of days stayed in bed (shown in Figure 1 ). In the MEPS, all respondents were asked about their employment article status and the main reason for not working. Respondents can choose one of the following options as the main reason for not working: 1) could not find work, 2) retired, 3) ill health, 4) on temporary layoff, 5) maternity/paternity leave, 6) going to school, 7) taking care of home or family, 8) wanted some time off, 9) wanting to start new job, 10) other. Therefore, employment disability was identified among those who were not employed with no job to return to and reported "unable to work because ill/disabled" as the main reason for both nonelderly and elderly populations. The number of missed work days was limited to nonelderly and elderly respondents who worked during the survey year. We used the probability of employment disability multiplied by 2012 annual median wage ($34 764) to calculate per capita wage loss (28) . Per capita productivity loss at work was calculated by multiplying the number of missed work days by the number of working hours (assuming 6 hours per day) and the 2012 median hourly wage ($16.7). Per capita productivity loss at home was calculated by multiplying the number of days stayed in bed by 2012 daily home productivity ($42). The total productivity loss is the sum of monetary measures of all three items.
Statistical Methods
Distributions of patient-level characteristics were examined and compared between cancer survivors and individuals without a cancer history using Pearson's chi-squared test. Adjusted analyses estimated medical expenditures and productivity losses among cancer survivors and individuals without a cancer history, controlling for differences in age, race/ethnicity, sex (colorectal cancer only), educational attainment, marital status, number of comorbid conditions, health insurance coverage (total medical expenditure only), and geographic region. Excess economic burden associated with cancer was measured by the differences in adjusted medical expenditures and productivity losses between cancer survivors and individuals without a cancer history. A generalized linear regression with a gamma distribution was utilized for medical expenditures. A logistic regression model was utilized to estimate the probability of employment disability, and a negative binomial regression was utilized for number of missed work days and days stayed in bed.
Predictive margins were generated in all adjusted analyses and used to estimate the excess economic burden faced by survivors of each cancer site (3, 29, 30) . Analytic files were created using SAS 9.3 (SAS Institute Inc, Cary, NC), and all regression analyses were performed using STATA 13.1 (StataCorp LP, College Station, TX) Command GLM. The MEPS sampling weights were used to account for the complex survey design and provide nationally representative estimates (31) . Statistical comparisons were two-sided, and statistical significance was defined at a P value of less than .05. Table 1 reports the distributions of patient-level characteristics between cancer survivors and individuals without a cancer history. Compared with those without a cancer history, we found that: 1) both nonelderly and elderly cancer survivors of all three major cancer sites were more likely to be older, non-Hispanic white, and have more comorbid conditions; 2) nonelderly cancer survivors were more likely to have higher family income; 3) elderly colorectal cancer survivors were less likely to be married but nonelderly breast and prostate cancer survivors were more likely to be married and privately insured. For the treatment status variable (Supplementary Table 1 , available online), we found that nonelderly colorectal cancer survivors (84.9%) were more likely to be receiving cancer-related treatment than elderly colorectal cancer survivors (52.4%) within two years since diagnosis and nonelderly prostate cancer survivors (27.2%) were less likely to be receiving cancer-related treatment than elderly prostate cancer survivors (43.2%) after two years since diagnosis. Figure 2 shows the total adjusted annual economic burden among cancer survivors, which is the sum of medical expenditures and productivity losses. For the nonelderly population, colorectal cancer was associated with the highest annual economic burden ($20 219), followed by breast cancer ($14 167) and * All statistical tests were two-sided, and all P values were calculated using Pearson's chi-squared test. Shaded area represents age group 18-64 years. † P value generated using a comparison group that included all individuals (both women and men) without a history of cancer from the same age group (18-64 or 65+ years). ‡ P value generated using a comparison group that included only women without a history of cancer from the same age group (18-64 or 65+ years). § P value generated using a comparison group that included only men without a history of cancer from the same age group (18-64 or 65+ years). ¶ All respondents reported "widowed," "divorced," "separated," or "never married" were grouped in the "not married" category.
Results
Distribution of Patient-Level Characteristics
Total Adjusted Annual Economic Burden Among Cancer Survivors
article prostate cancer ($9280). For the elderly population, the economic burden of colorectal cancer remained the highest ($19 051), followed by prostate cancer ($16 851) and breast cancer ($14 391) (all P < .001). The proportion of medical expenditures in total economic burden ranged from 60.7% for nonelderly colorectal cancer survivors to 74.6% for elderly breast cancer survivors. Figures 3 and 4 show the proportions of medical expenditures by source of payment and type of services. Private health insurance and Medicare represented the largest source of payment for nonelderly and elderly cancer survivors, respectively ( Figure 3) . Ambulatory care and inpatient care together accounted for more than 60% of total medical expenditures for each of the three cancer sites and age groups (Figure 4) . Detailed results of adjusted economic burden among cancer survivors across age groups and the three cancer sites are reported in Supplementary Table 2 (available online) . was associated with the greatest annual excess medical expenditures ($8647, 95% CI = $4932 to $13 974), followed by breast cancer ($5119, 95% CI = $3439 to $7158) and prostate cancer ($3586, 95% CI = $1792 to $6076) (all P < .001). For elderly cancer survivors, excess medical expenditures associated with colorectal cancer were the highest ($4913, 95% CI = $2768 to $7470, P < .001), followed by prostate cancer ($3524, 95% CI = $1539 to $5909, P < .001) and breast cancer ($2288, 95% CI = $814 to $3995, P = .002). For productivity losses, nonelderly colorectal cancer survivors experienced statistically significant excess productivity losses resulting from employment disability (13.6%, 95% CI = 6.1% to 25.9%), number of missed work days (7.2 days, 95% CI = 2.1 to 17.1 days), and number of days stayed in bed (4.5 days, 95% CI = 1.4 to 9.5 days). Nonelderly breast cancer survivors also faced statistically significant excess productivity losses from employment disability (4.8%, 95% CI = 1.7% to 9.2%), number of missed worked days (3.3 days, 95% CI = 1.0 to 6.6 days), and number of days stayed in bed (3.3 days, 95% CI = 0.9 to 6.8 days). Elderly colorectal and breast cancer survivors and nonelderly and elderly prostate cancer survivors generally experienced comparable productivity losses as individuals without a cancer history.
Excess Adjusted Annual Medical Expenditure and Productivity Loss Associated With Cancer
Discussion
In this study, we examined the annual economic burden among nonelderly and elderly colorectal, breast, and prostate cancer survivors using a nationally representative sample. We found that the total economic burden was similar across age groups for colorectal and breast cancer survivors but nearly twice as high for the elderly as the nonelderly prostate cancer survivors. Compared with individuals without a cancer history, both nonelderly and elderly cancer survivors face greater annual economic burden for all three major cancer sites. However, we found that the magnitude of excess economic burden varies by cancer site. For the nonelderly population, the annual excess medical expenditures were about $8600 for colorectal, $5100 for breast, and $3600 for prostate cancer. For the elderly population, the annual excess medical expenditures were about $4900 for colorectal, $2300 for breast, and $3500 for prostate cancer. Nonelderly colorectal and breast cancer survivors also bear statistically significant excess productivity losses. To our knowledge, this is the first study that provides a comprehensive analysis of medical expenditures and productivity losses in both nonelderly and elderly populations for the three most common cancers in the United States using contemporary, nationally representative data.
Compared with individuals without a cancer history, the statistically significantly higher medical expenditures among cancer survivors may reflect costs of treatments associated with cancer and comorbid conditions (8, 10, 32) . In our sample, close to 60% of the nonelderly cancer survivors had at least two additional comorbid conditions compared with approximately 23% of nonelderly individuals without a cancer history. Among the elderly population, about 80% of the cancer survivors had at least two additional comorbid conditions compared with approximately 75% of elderly individuals without a cancer history (Table 1) . Previous research linked comorbid conditions with high economic burden (23) (24) (25) (26) . The presence of comorbid conditions may also increase the likelihood of inability to work and time spent in bed.
In contrast to our findings for colorectal and breast cancer survivors, the patterns of total and excess economic burden measures by age group were different for prostate cancer survivors. This likely reflects differences in treatment patterns among survivors of these cancers by age group. Although the overall proportion of survivors receiving cancer-related treatment at the time of the MEPS was similar by cancer site and age group, we observed differences in nonelderly cancer survivors by cancer site when stratified by time since diagnosis (Supplementary Table 1 , available online). Among both recently and previously diagnosed nonelderly cancer survivors, prostate cancer was associated with lower likelihood of receiving cancerrelated treatments than colorectal and breast cancers. Although we do not have details on the specific chemotherapy regimens, article Table 2 hormone therapies, or types of surgery/radiation therapy received, others have reported differences in cancer-directed treatment by cancer site (1, 33) . The patterns of medical expenditures and productivity losses may also vary for survivors of other common cancers (eg, bladder, lung, melanoma, non-Hodgkin's lymphoma), but, unfortunately, we could not investigate other cancers in this study because of small sample sizes even with multiple years of the MEPS. Further evaluation of treatment patterns, medical expenditures, and productivity losses in large cohorts of newly diagnosed cancer patients with these and other cancers will be important for future research. Our findings may be particularly timely as the ACA is implemented. The ACA can reduce economic burden among cancer survivors in several ways (34) . Firstly, the ACA eliminated OOP cost for certain proven preventive services with most health plans (34) . With respect to survivors, the ACA removed prior health conditions as a barrier to health insurance coverage (34) . It will be important to continue monitoring the effect these policies may have in reducing economic burden among both nonelderly and elderly populations by cancer site. Our findings provide important information about the cancer site-specific economic burden prior to the implementation of ACA. Future research could evaluate the change in total and excess economic burden by cancer site in the post-ACA period. Moreover, our findings can be used in cost-effectiveness analysis to evaluate cancer survivorship programs or conduct budget impact analysis at the national level (4, 35, 36) .
Our study used multiple years of the MEPS to provide nationally representative estimates of annual medical expenditure and productivity loss of the three most common cancers in the United States. Another data source commonly used to estimate the cost of cancer care in the United States is Surveillance, Epidemiology, and End Results (SEER), linked with Medicare claims data. Studies using linked SEER-Medicare data can provide detailed medical expenditures by phase of care and/or therapies received to estimate both incidence and prevalence costs (4, 22, 36) . However, these data cannot be used to estimate productivity losses, and the little information that is available for the nonelderly population is for those beneficiaries eligible for Medicare because of permanent disability. Moreover, results from different studies that estimate either medical expenditures or productivity losses for a particular cancer site cannot be directly compared because of differences in data sources, populations, perspectives, and methodologies (15, 20, (22) (23) (24) . In contrast, our study has the advantage of providing estimates of medical expenditures and productivity losses in the same nationally representative population, using the same methods for all three major cancers in adult cancer survivors of all ages.
There are several limitations in this study. A few important clinical variables, such as stage at diagnosis (21, 37) , type of treatment(s) received (23) , and survival time (4), were not available in the MEPS. All cancer survivors were identified by self-report and may be subject to reporting biases. However, previous studies showed the agreement is high between medical records and self-reported cancer history (38, 39) . In addition, cost of care is much higher right after cancer diagnoses or near the end of life than the continuing phase of care (21, 40) . However, our sample is not large enough to be stratified by time since diagnosis, and we can only report annual estimates. In addition, we observed large variations for some of the estimated medical expenditures and productivity losses, which could also be because of small sample sizes. Finally, our study excluded economic burden associated with health care seeking (eg, transportation to and from care) (41) or that among informal caregivers (42) . In spite of these limitations, this is the first study to provide nationally representative estimates of the economic burden of cancer for nonelderly survivors of the three major cancers in the United States.
The economic burden of cancer is substantial in the United States, and the excess economic burden associated with cancer varies by cancer site and age for the three major cancer sites considered in this analysis. In general, nonelderly cancer survivors experience statistically significantly greater excess medical expenditures and productivity losses compared with elderly cancer survivors. Understanding how the economic burden varies by cancer site and age is important to shape health care policies to target areas where cancer survivors are most vulnerable.
